These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


746 related items for PubMed ID: 11520154

  • 1. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
    Robinson JB, Singh D, Bodurka-Bevers DC, Wharton JT, Gershenson DM, Wolf JK.
    Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
    [Abstract] [Full Text] [Related]

  • 2. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
    [Abstract] [Full Text] [Related]

  • 3. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.
    Lee CW, Matulonis UA, Castells MC.
    Gynecol Oncol; 2004 Nov; 95(2):370-6. PubMed ID: 15491759
    [Abstract] [Full Text] [Related]

  • 4. [Successful desensitization using cisplatin after carboplatin-associated hypersensitivity reactions in 3 cases with recurrent ovarian carcinoma].
    Hosaka M, Ebina Y, Moriwaki M, Hara Y, Araki N, Todo Y, Takeda M, Watari H, Sakuragi N.
    Gan To Kagaku Ryoho; 2007 Sep; 34(9):1505-8. PubMed ID: 17876157
    [Abstract] [Full Text] [Related]

  • 5. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
    Feldweg AM, Lee CW, Matulonis UA, Castells M.
    Gynecol Oncol; 2005 Mar; 96(3):824-9. PubMed ID: 15721432
    [Abstract] [Full Text] [Related]

  • 6. Carboplatin desensitization.
    Choi J, Harnett P, Fulcher DA.
    Ann Allergy Asthma Immunol; 2004 Aug; 93(2):137-41. PubMed ID: 15328672
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
    Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF.
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
    [Abstract] [Full Text] [Related]

  • 10. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
    Ottaiano A, Tambaro R, Greggi S, Prato R, Di Maio M, Esposito G, Scala F, Barletta E, Losito S, De Vivo R, Iaffaioli VR, Pignata S.
    Anticancer Res; 2003 Dec; 23(4):3465-8. PubMed ID: 12926091
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy.
    Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J.
    Gynecol Oncol; 2000 Jul; 78(1):43-6. PubMed ID: 10873408
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
    Kwon JS, Elit L, Finn M, Hirte H, Mazurka J, Moens F, Trim K.
    Gynecol Oncol; 2002 Mar; 84(3):420-5. PubMed ID: 11855881
    [Abstract] [Full Text] [Related]

  • 15. Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J.
    Gynecol Oncol; 1998 Oct; 71(1):113-5. PubMed ID: 9784330
    [Abstract] [Full Text] [Related]

  • 16. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
    J Clin Oncol; 2006 Feb 01; 24(4):579-86. PubMed ID: 16446330
    [Abstract] [Full Text] [Related]

  • 17. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital.
    Schwartz JR, Bandera C, Bradley A, Brard L, Legare R, Granai CO, Dizon DS.
    Gynecol Oncol; 2007 Apr 01; 105(1):81-3. PubMed ID: 17157366
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
    Kietpeerakool C, Suprasert P, Srisomboon J.
    J Med Assoc Thai; 2005 Mar 01; 88(3):301-6. PubMed ID: 15962635
    [Abstract] [Full Text] [Related]

  • 20. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
    Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, Wong JT.
    J Allergy Clin Immunol; 2009 Jun 01; 123(6):1262-7.e1. PubMed ID: 19501233
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 38.